IL1RL2 and Alzheimer disease: Recently, a modest efficacy of an anti-IL-36 receptor antibody in patients with moderate-to-severe AD was demonstrated in a clinical trial, suggesting that the IL-36 pathway does not play a major role in the pathogenesis of AD [36].